OCT 29, 2020 9:37 PM PDT

Scientists Create Antibiotic from Komodo Dragon Blood

WRITTEN BY: Annie Lennon

Researchers from George Mason University in Washington DC have created a synthetic molecule from Komodo Dragon blood that, from early results, has shown to be a powerful antibiotic. 

Komodo Dragons are an endangered species of monitor lizard found on five Indonesian islands. Known for their large size and venomous bite, they have over 80 strains of bacteria in their mouths, some of which cause severe blood poison in bite humans and animals, although not the dragon itself. They are also known for their ability to survive severe wounds, including lost limbs, without getting infected, despite the filthy environments they live in. 

Given that finding new drugs is ‘critical’ to counteract increasing rates of drug resistance, researchers are investigating the mechanisms behind the Komodo’s Dragon’s stunning immunity. 

In the present study, the researchers created a drug called DRGN-6 by combining two genes found in Komodo Dragon blood. Preclinical tests found it was able to kill carbapenem-resistant Klebsiella pneumoniae, a highly drug-resistant bacteria known to cause an aggressive form of pneumonia that kills up to 600 people in the US per year. Further tests also showed that DRGN-6 is safe to use in waxworms. 

These results follow findings from a 2017 paper stating that another synthetic molecule from Komodo Dragon blood, known as DRGN-1, is able to promote healing of wounds infected with Pseudomonas aeruginosa and Staphylococcus aureus (also known as MRSA) in mice. 

While promising findings, the researchers behind the drugs say that it could take around a decade before they reach the market. This comes as they first need to be tweaked via a process known as rational design to ensure they cause no damage to red blood cells. Following this, they will need to be shown as effective in both animal studies and human trials. 

 

Sources: NY PostTelegraphJournal of Medical Microbiology

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
NOV 29, 2022
Drug Discovery & Development
Chemotherapy May Increase Disease Susceptibility for Two Generations
Chemotherapy May Increase Disease Susceptibility for Two Generations
A common chemotherapy drug may make future generations more susceptible to disease. The corresponding study was publishe ...
DEC 06, 2022
Drug Discovery & Development
Cannabinoids Fail to Improve Measures of Pain Intensity Above Placebo
Cannabinoids Fail to Improve Measures of Pain Intensity Above Placebo
Cannabinoids are commonly prescribed for conditions such as back and cancer pain. However, evidence that it offers an an ...
DEC 14, 2022
Drug Discovery & Development
The Two Brains Exposed by Ketamine
The Two Brains Exposed by Ketamine
Researchers out of the University of Pennsylvania have discovered our brains are split in two and not just along the hem ...
JAN 04, 2023
Health & Medicine
ACER-001- New Drug to Treat Genetic Disorder
ACER-001- New Drug to Treat Genetic Disorder
Urea cycle disorders (UCDs) are genetic conditions most commonly diagnosed in children that result in the body&rsqu ...
JAN 24, 2023
Immunology
Remove Dead Cells for Increased Accuracy
Remove Dead Cells for Increased Accuracy
Even viability dyes need controls. Don’t have time to “kill” a control for this? Don’t worry- we ...
JAN 04, 2023
Clinical & Molecular DX
Dual-Action Cancer Vaccine Targets Brain Tumors Directly
Dual-Action Cancer Vaccine Targets Brain Tumors Directly
Scientists have developed a new, targeted strategy to eliminate brain tumors and prevent future recurrences of brain can ...
Loading Comments...